Press Release

The Ivy Center proudly announces our participation in the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting for two Phase 0 clinical trials of infigratinib and niraparib in recurrent high-grade glioma and newly-diagnosed glioblastoma.

The Ivy Brain Tumor Center and Barrow Neurological Institute are pleased to announce the addition of Yoshie Umemura, MD, as the new Chief Medical Officer of the Ivy Brain Tumor Center and Division Chief of Neuro-Oncology and the William and Joan Shapiro Chair of Neuro-Oncology at Barrow Neurological Institute. 

The Ivy Brain Tumor Center is leading the way in brain cancer research and treatment. May is Brain Tumor Awareness Month and the Ivy Center has partnered with several major organizations across the state to bring much-needed attention to and support for Brain Tumor Awareness Month.

Dr. An-Chi Tien, Pharmacodynamics Core Leader of the Ivy Center, is the recipient of the American Brain Tumor Association’s Discovery Grant, a one-year, $50,000 award, supporting faculty and scientists who propose high-risk, high-impact research with the potential to change current diagnostic or treatment models for brain tumor care. 

Presented today at the ESMO Congress, Dr. Nader Sanai announced initial results in our Phase 0 clinical trial evaluating pamiparib in patients with #glioblastoma (NCT04614909). The interim analysis demonstrated that pamiparib is well-tolerated in glioblastoma patients.

The Ivy Brain Tumor Center announced its initiation of a ‘Liquid Biopsy’ program to obtain real-time insights into how a patient’s brain tumor is responding to experimental treatment. 

Ivy Brain Tumor Center has launched a new Spanish-language website, providing information and resources about brain cancer for Spanish-speaking communities. Check it out now.

Ivy Brain Tumor Center is conducting a new clinical trial for patients with recurrent Grade IV gliomas. Learn about the study and how it could improve brain cancer treatments.

The Ivy Brain Tumor Center, the largest early-phase drug development program for brain cancer in the world, announced that its Pharmacodynamics (PD) Core and Pharmacokinetics (PK) Core laboratories passed their inspection and maintained accreditation by the Accreditation Committee of the College of American Pathologists (CAP).

The Ivy Center in collaboration with UCSF Department of Neurological Surgery is pleased to announce a new clinical trial of GSK’s niraparib (ZEJULA) – an FDA-approved drug to treat ovarian cancer – for patients with newly diagnosed glioblastoma and recurrent high-grade gliomas.